Price cuts loom on latest pre-AMNOG call up
This article was originally published in Scrip
Executive Summary
Companies like Servier, Johnson & Johnson, and Amgen facing a retrospective AMNOG benefit assessment in Germany would do well to seek advice from the G-BA, the committee in charge of the process, as soon as possible, advises EUCOPE, the European Confederation of Pharmaceutical Entrepreneurs. Such firms will need to know not only what data they need to produce, but also whether they qualify for reduced data requirements, said Matthias Heck, EUCOPE's legal counsel.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.